サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1120306

レジオネラ菌検査の世界市場：検査の種類別 (培養、尿中抗原検査、DFA、PCR)・用途別 (水質検査、体外診断 (尿、血液))・エンドユーザー別 (病院、診療所、診断検査室、水処理産業)・地域別の将来予測 (2027年まで)

Legionella Testing Market by Test Type (Culture, Urinary Antigen Test, DFA, PCR), Application (Water & IVD Testing (Urine, Blood)), End User (Hospitals, Clinics, Diagnostic Labs, Water Treatment Industries), Region - Global Forecast to 2027
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 203 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
レジオネラ菌検査の世界市場：検査の種類別 (培養、尿中抗原検査、DFA、PCR)・用途別 (水質検査、体外診断 (尿、血液))・エンドユーザー別 (病院、診療所、診断検査室、水処理産業)・地域別の将来予測 (2027年まで)
出版日: 2022年08月17日
発行: MarketsandMarkets
ページ情報: 英文 203 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

レジオネラ菌検査の世界市場は、2022年の2億9,600万米ドルから2027年には4億3,900万米ドルに達すると予測され、予測期間中のCAGRは8.2%となります。

この市場の成長は主に、レジオネラ関連疾患の有病率の上昇と相まって老年人口が増加していることと、迅速な診断に対する需要が高まっていることに起因しています。

検査の種類別では、2021年にはPCR分野が成長率が最も高くなっています。PCR検査の速度・汎用性・簡便性が市場成長の主な要因となっています。

エンドユーザー別では2021年に、水道・その他の産業セグメントが最も高い成長率を占めました。その要因として、人口増加や都市化、新たな水資源に対する需要の増加などが挙げられます。

地域別に見ると、アジア太平洋が予測期間中に最も高いCAGRを記録すると予測されています。病気の早期診断や定期的な健康診断に関する意識を高めるための政府の取り組みなどが、主な要因として挙げられます。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
  • 価格分析
  • 特許分析
  • バリューチェーン分析
  • サプライチェーン分析
  • エコシステム/マーケットマップ
  • ポーターのファイブフォース分析
  • PESTEL分析
  • 規制状況
  • 貿易分析
    • 診断用・検査用試薬の取引分析
  • 技術分析
  • 主な会議とイベント (2022年～2023年)
  • 顧客のビジネスに影響を与える動向/混乱
  • 主な利害関係者と購入基準
  • ケーススタディ

第6章 レジオネラ菌検査市場：検査の種類別

  • イントロダクション
  • PCR
  • 培養
  • 尿中抗原検査
  • 直接蛍光抗体 (DFA) 検査

第7章 レジオネラ菌検査市場：用途別

  • イントロダクション
  • 水質検査
    • PCR
    • 微生物培養
    • DFAステイン
  • IVD (体外診断) 検査
    • 尿中抗原検査
    • PCR
    • 血液培養・喀痰検査
    • DFAステイン
  • その他の用途

第8章 レジオネラ菌検査市場：エンドユーザー別

  • イントロダクション
  • 水道産業・その他の産業
  • 診断検査室
  • 病院
  • その他のエンドユーザー

第9章 レジオネラ菌検査市場：地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • 他の欧州諸国
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 他のアジア太平洋諸国
  • ラテンアメリカ
  • 中東・アフリカ

第10章 競合情勢

  • 概要
  • 主要企業の戦略/有力企業
  • 主要企業の収益シェア分析
  • 市場シェア分析
  • 企業評価マトリックス
  • 競合リーダーシップマッピング (2021年)
  • 競合ベンチマーキング
    • 製品別・地域別のフットプリント分析
  • 競合シナリオ
    • 製品の発売
    • 資本取引
    • その他の開発

第11章 企業プロファイル

  • 主要企業
    • 産業/水道
      • Thermo Fisher Scientific
      • Merck KGAA
      • Bio-Rad Laboratories
      • IDEXX Laboratories
      • Biomerieux SA
      • Becton, Dickinson and Company
      • Eurofins Scientific
      • Takara Bio
      • Qiagen
      • Genomadix
  • その他の企業
    • 産業/水道
      • Pall Corporation (DANAHER)
      • Phigenics, Llc
      • Environmental safety technologies
      • Hydrosense
      • Accepta
      • Luminultra technologies
      • Bioalert solutions
      • Aquacert
      • Pacific water technology
      • DTK Water
      • Sens solutions
    • 医療
      • Alere (ABBOTT)
      • Roche Diagnostics
      • Hologic
      • Quidel Corporation
      • Pro-Lab Diagnostics

第12章 付録

目次
Product Code: MD 8150

The global legionella testing market is projected to reach USD 439 million by 2027 from USD 296 million in 2022, at a CAGR of 8.2% during the forecast period. Growth in this market is mainly driven by the rising geriatric population coupled with increasing prevalence of legionella-related illness, and rising demand for rapid diagnostics.

"The PCR segment accounted for the highest growth rate in the legionella testing market, by test type, during the forecast period."

The legionella testing market is segmented into culture methods, urinary antigen tests, direct fluorescent antibody tests, and PCR based on product. In 2021, the PCR segment accounted for the highest growth rate in the legionella testing market. Market growth can largely be attributed to its speed, versatility, and simplicity.

"Water & Other Industries segment accounted for the highest CAGR."

Based on the end user, the legionella testing market has been segmented into hospitals, diagnostic laboratories, water & other industries, and other end user. In 2021, the water & other industries segment accounted for the highest growth rate. This can be attributed to the rising population and urbanization, and the increased demand for new water resources

"Asia Pacific: The fastest-growing region legionella testing market."

The global legionella testing market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Factors such as government efforts to increase awareness about the early disease diagnosis and regular health check-ups

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 -30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America -51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and the Middle East & Africa - 4%

Lists of Companies Profiled in the Report:

  • Thermo Fisher Scientific, Inc. (US)
  • Merck KGaA (Germany)
  • Bio-Rad Laboratories, Inc. (US)
  • IDEXX Laboratories, Inc. (US)
  • bioMerieux S.A. (France)
  • Becton, Dickinson, and Company (US)
  • Alere, Inc. (US)
  • Eurofins Scientific (Luxembourg)
  • Roche Diagnostics (Switzerland)
  • Pall Corporation (Danaher) (US)
  • Quidel Corporation (US)
  • Eiken Chemical Co., Ltd. (Japan)
  • Hologic, Inc. (US)
  • QIAGEN (Germany)
  • Takara Bio, Inc. (Japan)
  • Environmental Safety Technologies, Inc. (US)
  • Hydrosense (Scotland)
  • Accepta Ltd. (UK)
  • LuminUltra Technologies Ltd. (Canada)
  • Pro-Lab Diagnostics, Inc. (Canada)
  • BioAlert Solutions (Canada)
  • Pacific Water Technology (Australia)
  • Aquacert Ltd. (UK)
  • DTK Water (UK)
  • Sens Solutions (Spain)
  • Genomadix, Inc. (US)
  • Phigenics, LLC (US).

Research Coverage:

This report provides a detailed picture of the global legionella testingmarket. It aims at estimating the size and future growth potential of the market across different segments, such as test type, application, end user, and region. The report also includes an in-depth competitive analysis of the key market player, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall legionella testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • TABLE 1 INCLUSIONS AND EXCLUSIONS
  • 1.3 STUDY SCOPE
  • 1.4 YEARS CONSIDERED
  • 1.5 CURRENCY CONSIDERED
  • 1.6 LIMITATIONS
  • 1.7 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 LEGIONELLA TESTING MARKET: RESEARCH DESIGN METHODOLOGY
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
    • TABLE 2 KEY DATA FROM PRIMARY SOURCES
    • FIGURE 2 KEY INDUSTRY INSIGHTS
      • 2.1.2.2 Breakdown of primary interviews
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (LEGIONELLA TESTING MARKET)
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
      • 2.2.1.2 Approach 2: Presentations of companies and primary interviews
      • 2.2.1.3 Growth forecast
      • 2.2.1.4 CAGR projections
    • FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.2.2 TOP-DOWN APPROACH
    • FIGURE 7 LEGIONELLA TESTING MARKET: TOP-DOWN APPROACH
  • 2.3 DATA TRIANGULATION
    • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • 2.4 RESEARCH ASSUMPTIONS
  • 2.5 LIMITATIONS AND RISK ASSESSMENT
    • FIGURE 9 LIMITATIONS: LEGIONELLA TESTING MARKET
    • TABLE 3 RISK ASSESSMENT: LEGIONELLA TESTING MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 10 LEGIONELLA TESTING MARKET, BY TEST TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 11 LEGIONELLA TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 12 LEGIONELLA TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 13 LEGIONELLA TESTING MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 LEGIONELLA TESTING MARKET OVERVIEW
    • FIGURE 14 GROWING PREVALENCE OF LEGIONELLA-RELATED ILLNESS AND RISING GERIATRIC POPULATION TO DRIVE MARKET GROWTH
  • 4.2 LEGIONELLA TESTING MARKET SHARE, BY TEST TYPE, 2022 VS. 2027
    • FIGURE 15 PCR SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2027
  • 4.3 LEGIONELLA TESTING MARKET SHARE, BY APPLICATION, 2022 VS. 2027
    • FIGURE 16 WATER TESTING SEGMENT TO HOLD LARGEST MARKET SHARE
  • 4.4 LEGIONELLA TESTING MARKET SHARE, BY END USER, 2022 VS. 2027
    • FIGURE 17 WATER & OTHER INDUSTRIES TO CONTINUE TO DOMINATE MARKET IN 2027
  • 4.5 LEGIONELLA TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 LEGIONELLA TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising incidence of pneumonia and legionella-related illnesses
      • 5.2.1.2 Increasing demand for rapid advanced diagnostic technologies
      • 5.2.1.3 Technological advancements in bacterial testing
      • 5.2.1.4 Stringent regulations for regular water testing
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Lack of reimbursement policies
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Opportunities in growing economies
      • 5.2.3.2 Legal requirements for water testing
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Difficulties in detection
      • 5.2.4.2 Limited awareness in underdeveloped countries
      • 5.2.4.3 High health costs associated with Legionella
  • 5.3 PRICING ANALYSIS
    • TABLE 4 AVERAGE SELLING PRICE OF LEGIONELLA TESTING PRODUCTS (2022)
  • 5.4 PATENT ANALYSIS
    • FIGURE 20 PATENT ANALYSIS FOR MOTORIZED LEGIONELLA TESTING DEVICES
    • TABLE 5 LIST OF KEY PATENTS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 22 LEGIONELLA TESTING MARKET: SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM/MARKET MAP
    • FIGURE 23 LEGIONELLA TESTING MARKET: ECOSYSTEM/MARKET MAP
    • TABLE 6 LEGIONELLA TESTING MARKET: ROLE IN ECOSYSTEM
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 7 LEGIONELLA TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 BARGAINING POWER OF SUPPLIERS
    • 5.8.5 DEGREE OF COMPETITION
  • 5.9 PESTEL ANALYSIS
    • 5.9.1 POLITICAL FACTORS
    • 5.9.2 ECONOMIC FACTORS
    • 5.9.3 SOCIAL FACTORS
    • 5.9.4 TECHNOLOGICAL FACTORS
    • 5.9.5 ENVIRONMENTAL FACTORS
    • 5.9.6 LEGAL FACTORS
  • 5.10 REGULATORY LANDSCAPE
    • TABLE 8 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 11 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.10.1 NORTH AMERICA
      • 5.10.1.1 US
      • 5.10.1.2 Canada
    • 5.10.2 EUROPE
    • 5.10.3 ASIA PACIFIC
      • 5.10.3.1 Japan
      • 5.10.3.2 India
    • 5.10.4 LATIN AMERICA
      • 5.10.4.1 Brazil
      • 5.10.4.2 Mexico
    • 5.10.5 MIDDLE EAST
    • 5.10.6 AFRICA
  • 5.11 TRADE ANALYSIS
    • 5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
    • TABLE 13 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017-2021 (USD MILLION)
    • TABLE 14 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017-2021 (USD MILLION)
  • 5.12 TECHNOLOGY ANALYSIS
  • 5.13 KEY CONFERENCES & EVENTS IN 2022-2023
    • TABLE 15 LEGIONELLA TESTING MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 24 REVENUE SHIFT IN THE LEGIONELLA TESTING MARKET
  • 5.15 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 25 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF LEGIONELLA TESTING PRODUCTS
    • TABLE 16 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF LEGIONELLA TESTING PRODUCTS
    • 5.15.2 BUYING CRITERIA
    • FIGURE 26 KEY BUYING CRITERIA FOR LEGIONELLA TESTING PRODUCTS
    • TABLE 17 KEY BUYING CRITERIA FOR LEGIONELLA TESTING PRODUCTS
  • 5.16 CASE STUDIES

6 LEGIONELLA TESTING MARKET, BY TEST TYPE

  • 6.1 INTRODUCTION
    • TABLE 18 LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
  • 6.2 PCR
    • 6.2.1 INCREASED USAGE OF PCR TO SUPPORT MARKET GROWTH
    • TABLE 19 KEY PCR PRODUCTS AVAILABLE IN THE MARKET
    • TABLE 20 LEGIONELLA TESTING MARKET FOR PCR, BY REGION, 2020-2027 (USD MILLION)
  • 6.3 CULTURE METHODS
    • 6.3.1 HIGHER SPECIFICITY AND SENSITIVITY TO DRIVE MARKET
    • TABLE 21 KEY CULTURE METHODS AVAILABLE IN THE MARKET
    • TABLE 22 LEGIONELLA TESTING MARKET FOR CULTURE METHODS, BY REGION, 2020-2027 (USD MILLION)
  • 6.4 URINARY ANTIGEN TESTS
    • 6.4.1 RAPID OUTCOMES TO DRIVE MARKET GROWTH
    • TABLE 23 KEY URINARY ANTIGEN TESTS AVAILABLE IN THE MARKET
    • TABLE 24 LEGIONELLA TESTING MARKET FOR URINARY ANTIGEN TESTS, BY REGION, 2020-2027 (USD MILLION)
  • 6.5 DIRECT FLUORESCENT ANTIBODY TESTS
    • 6.5.1 RAPIDITY AND EASE OF USE TO BOOST ADOPTION OF TESTS
    • TABLE 25 LEGIONELLA TESTING MARKET FOR DIRECT FLUORESCENT ANTIBODY TESTS, BY REGION, 2020-2027 (USD MILLION)

7 LEGIONELLA TESTING MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 26 LEGIONELLA TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 7.2 WATER TESTING
    • TABLE 27 LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 28 LEGIONELLA TESTING MARKET FOR WATER TESTING, BY REGION, 2020-2027 (USD MILLION)
    • 7.2.1 PCR
      • 7.2.1.1 Rapid diagnosis to spur segment growth
    • TABLE 29 WATER TESTING MARKET FOR PCR, BY REGION, 2020-2027 (USD MILLION)
    • 7.2.2 MICROBIAL CULTURE
      • 7.2.2.1 Long incubation periods make isolation difficult, affecting adoption of culture techniques
    • TABLE 30 WATER TESTING MARKET FOR MICROBIAL CULTURE, BY REGION, 2020-2027 (USD MILLION)
    • 7.2.3 DFA STAIN
      • 7.2.3.1 High test specificity to drive adoption of DFA staining
    • TABLE 31 WATER TESTING MARKET FOR DFA STAIN, BY REGION, 2020-2027 (USD MILLION)
  • 7.3 IVD TESTING
    • TABLE 32 LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 33 LEGIONELLA TESTING MARKET FOR IVD TESTING, BY REGION, 2020-2027 (USD MILLION)
    • 7.3.1 URINE ANTIGEN TESTS
      • 7.3.1.1 Rapid and early diagnosis capabilities to drive market growth
    • TABLE 34 IVD TESTING MARKET FOR URINE ANTIGEN TESTS, BY REGION, 2020-2027 (USD MILLION)
    • 7.3.2 PCR
      • 7.3.2.1 Emergence of advanced technologies such as qRT-PCR to support market growth
    • TABLE 35 IVD TESTING MARKET FOR PCR, BY REGION, 2020-2027 (USD MILLION)
    • 7.3.3 BLOOD CULTURE & SPUTUM TESTS
      • 7.3.3.1 Longer incubation period resulting in lower adoption of blood culture techniques
    • TABLE 36 IVD TESTING MARKET FOR BLOOD CULTURE & SPUTUM TESTS, BY REGION, 2020-2027 (USD MILLION)
    • 7.3.4 DFA STAIN
      • 7.3.4.1 Sensitivity variations affect use of DFA staining in IVD tests
    • TABLE 37 IVD TESTING MARKET FOR DFA STAIN, BY REGION, 2020-2027 (USD MILLION)
  • 7.4 OTHER APPLICATIONS
    • TABLE 38 LEGIONELLA TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)

8 LEGIONELLA TESTING MARKET, BY END USER

  • 8.1 INTRODUCTION
    • TABLE 39 LEGIONELLA TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 8.2 WATER & OTHER INDUSTRIES
    • 8.2.1 STRINGENT REGULATIONS AND GROWING POPULATION TO DRIVE MARKET GROWTH
    • TABLE 40 LEGIONELLA TESTING MARKET FOR WATER & OTHER INDUSTRIES, BY REGION, 2020-2027 (USD MILLION)
  • 8.3 DIAGNOSTIC LABORATORIES
    • 8.3.1 HEALTHCARE INFRASTRUCTURE IMPROVEMENTS TO BOOST MARKET GROWTH
    • TABLE 41 LEGIONELLA TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020-2027 (USD MILLION)
  • 8.4 HOSPITALS
    • 8.4.1 INCREASING ADOPTION OF DIAGNOSTIC TOOLS TO SUPPORT MARKET GROWTH
    • TABLE 42 LEGIONELLA TESTING MARKET FOR HOSPITALS, BY REGION, 2020-2027 (USD MILLION)
  • 8.5 OTHER END USERS
    • TABLE 43 LEGIONELLA TESTING MARKET FOR OTHER END USERS, BY REGION, 2020-2027 (USD MILLION)

9 LEGIONELLA TESTING MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 44 LEGIONELLA TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 27 NORTH AMERICA: LEGIONELLA TESTING MARKET SNAPSHOT
    • TABLE 45 NORTH AMERICA: LEGIONELLA TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 46 NORTH AMERICA: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
    • TABLE 47 NORTH AMERICA: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 48 NORTH AMERICA: LEGIONELLA TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.2.1 US
      • 9.2.1.1 Strong presence of major market players to drive growth
    • TABLE 49 US: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
    • TABLE 50 US: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 51 US: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 52 US: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 53 US: LEGIONELLA TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Rising incidence of lifestyle diseases to drive market growth
    • TABLE 54 CANADA: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
    • TABLE 55 CANADA: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 56 CANADA: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 57 CANADA: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 58 CANADA: LEGIONELLA TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.3 EUROPE
    • TABLE 59 EUROPE: LEGIONELLA TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 60 EUROPE: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
    • TABLE 61 EUROPE: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 62 EUROPE: LEGIONELLA TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.1 GERMANY
      • 9.3.1.1 Germany dominates Legionella testing market in Europe
    • TABLE 63 GERMANY: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
    • TABLE 64 GERMANY: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 65 GERMANY: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 66 GERMANY: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 67 GERMANY: LEGIONELLA TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.2 UK
      • 9.3.2.1 Growing number of accredited diagnostic laboratories to propel market growth
    • TABLE 68 UK: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
    • TABLE 69 UK: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 70 UK: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 71 UK: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 72 UK: LEGIONELLA TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.3 FRANCE
      • 9.3.3.1 Rising R&D expenditure and increasing demand for early diagnosis to drive market growth
    • TABLE 73 FRANCE: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
    • TABLE 74 FRANCE: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 75 FRANCE: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 76 FRANCE: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 77 FRANCE: LEGIONELLA TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.4 ITALY
      • 9.3.4.1 Adoption of advanced diagnostic technologies to drive market growth
    • TABLE 78 ITALY: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
    • TABLE 79 ITALY: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 80 ITALY: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 81 ITALY: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 82 ITALY: LEGIONELLA TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.5 SPAIN
      • 9.3.5.1 Rising geriatric population to drive market growth
    • TABLE 83 SPAIN: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
    • TABLE 84 SPAIN: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 85 SPAIN: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 86 SPAIN: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 87 SPAIN: LEGIONELLA TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.6 REST OF EUROPE
    • TABLE 88 ROE: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
    • TABLE 89 ROE: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 90 ROE: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 91 ROE: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 92 ROE: LEGIONELLA TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.4 ASIA PACIFIC
    • FIGURE 28 APAC: LEGIONELLA TESTING MARKET SNAPSHOT
    • TABLE 93 ASIA PACIFIC: LEGIONELLA TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 94 ASIA PACIFIC: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
    • TABLE 95 ASIA PACIFIC: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 96 ASIA PACIFIC: LEGIONELLA TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.1 CHINA
      • 9.4.1.1 Growing public access to modern healthcare to drive market growth
    • TABLE 97 CHINA: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
    • TABLE 98 CHINA: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 99 CHINA: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 100 CHINA: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 101 CHINA: LEGIONELLA TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.2 JAPAN
      • 9.4.2.1 Universal healthcare reimbursement policy to drive market growth
    • TABLE 102 JAPAN: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
    • TABLE 103 JAPAN: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 104 JAPAN: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 105 JAPAN: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 106 JAPAN: LEGIONELLA TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.3 INDIA
      • 9.4.3.1 Increasing private & public investments in healthcare to drive market growth
    • TABLE 107 INDIA: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
    • TABLE 108 INDIA: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 109 INDIA: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 110 INDIA: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 111 INDIA: LEGIONELLA TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.4 REST OF ASIA PACIFIC
    • TABLE 112 ROAPAC: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
    • TABLE 113 ROAPAC: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 114 ROAPAC: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 115 ROAPAC: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 116 ROAPAC: LEGIONELLA TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.5 LATIN AMERICA
    • 9.5.1 RISING HEALTHCARE EXPENDITURE TO DRAW FOREIGN PLAYERS
    • TABLE 117 LATIN AMERICA: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
    • TABLE 118 LATIN AMERICA: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 119 LATIN AMERICA: LEGIONELLA TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.6 MIDDLE EAST & AFRICA
    • 9.6.1 RISING ACCESS TO ADVANCED TECHNOLOGIES AND GROWING INVESTMENTS TO SUPPORT MARKET GROWTH
    • TABLE 120 MIDDLE EAST & AFRICA: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020-2027 (USD MILLION)
    • TABLE 121 MIDDLE EAST & AFRICA: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 122 MIDDLE EAST & AFRICA: LEGIONELLA TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 10.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE LEGIONELLA TESTING MARKET
    • TABLE 123 STRATEGIC DEVELOPMENTS REPORTED
  • 10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 29 REVENUE SHARE ANALYSIS OF TOP PLAYERS
  • 10.4 MARKET SHARE ANALYSIS
    • 10.4.1 LEGIONELLA TESTING MARKET
    • FIGURE 30 LEGIONELLA TESTING MARKET SHARE, BY KEY PLAYER (2021)
    • TABLE 124 LEGIONELLA TESTING MARKET: DEGREE OF COMPETITION
  • 10.5 COMPANY EVALUATION MATRIX
    • 10.5.1 LIST OF EVALUATED VENDORS
    • 10.5.2 STARS
    • 10.5.3 EMERGING LEADERS
    • 10.5.4 PERVASIVE PLAYERS
    • 10.5.5 PARTICIPANTS
    • FIGURE 31 LEGIONELLA TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
  • 10.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021)
    • 10.6.1 PROGRESSIVE COMPANIES
    • 10.6.2 STARTING BLOCKS
    • 10.6.3 RESPONSIVE COMPANIES
    • 10.6.4 DYNAMIC COMPANIES
    • FIGURE 32 LEGIONELLA TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
  • 10.7 COMPETITIVE BENCHMARKING
    • 10.7.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS
    • FIGURE 33 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN LEGIONELLA TESTING MARKET
    • TABLE 125 LEGIONELLA TESTING MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
    • TABLE 126 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS
    • TABLE 127 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
    • TABLE 128 LEGIONELLA TESTING MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • 10.8 COMPETITIVE SCENARIO
    • 10.8.1 PRODUCT LAUNCHES
    • TABLE 129 LEGIONELLA TESTING MARKET: KEY PRODUCT LAUNCHES & REGULATORY APPROVALS
    • 10.8.2 DEALS
    • TABLE 130 LEGIONELLA TESTING MARKET: KEY DEALS
    • 10.8.3 OTHER DEVELOPMENTS
    • TABLE 131 LEGIONELLA TESTING MARKET: OTHER DEVELOPMENTS

11 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, MnM View SWOT analysis) **
  • 11.1 KEY PLAYERS
    • 11.1.1 INDUSTRIAL/WATER
      • 11.1.1.1 Thermo Fisher Scientific
    • TABLE 132 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 34 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021)
      • 11.1.1.2 Merck KGAA
    • TABLE 133 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 35 MERCK KGAA: COMPANY SNAPSHOT (2021)
      • 11.1.1.3 Bio-Rad Laboratories
    • TABLE 134 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 36 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)
      • 11.1.1.4 IDEXX Laboratories
    • TABLE 135 IDEXX LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 37 IDEXX LABORATORIES: COMPANY SNAPSHOT (2021)
      • 11.1.1.5 Biomerieux SA
    • TABLE 136 BIOMERIEUX SA: BUSINESS OVERVIEW
    • FIGURE 38 BIOMERIEUX SA: COMPANY SNAPSHOT (2021)
      • 11.1.1.6 Becton, Dickinson and Company
    • TABLE 137 BECTON, DICKINSON, AND COMPANY: BUSINESS OVERVIEW
    • FIGURE 39 BECTON, DICKINSON, AND COMPANY: COMPANY SNAPSHOT (2021)
      • 11.1.1.7 Eurofins Scientific
    • TABLE 138 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 40 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021)
      • 11.1.1.8 Takara Bio
    • TABLE 139 TAKARA BIO: BUSINESS OVERVIEW
    • FIGURE 41 TAKARA BIO: COMPANY SNAPSHOT (2021)
      • 11.1.1.9 Eiken Chemical
    • TABLE 140 EIKEN CHEMICAL: BUSINESS OVERVIEW
    • FIGURE 42 EIKEN CHEMICAL: COMPANY SNAPSHOT (2021)
      • 11.1.1.10 Qiagen
    • TABLE 141 QIAGEN: BUSINESS OVERVIEW
    • FIGURE 43 QIAGEN: COMPANY SNAPSHOT (2021)
      • 11.1.1.11 Genomadix
    • TABLE 142 GENOMADIX, INC.: BUSINESS OVERVIEW
  • 11.2 OTHER PLAYERS
    • 11.2.1 INDUSTRIAL/WATER
      • 11.2.1.1 Pall Corporation (DANAHER)
      • 11.2.1.2 Phigenics, Llc
      • 11.2.1.3 Environmental safety technologies
      • 11.2.1.4 Hydrosense
      • 11.2.1.5 Accepta
      • 11.2.1.6 Luminultra technologies
      • 11.2.1.7 Bioalert solutions
      • 11.2.1.8 Aquacert
      • 11.2.1.9 Pacific water technology
      • 11.2.1.10 DTK Water
      • 11.2.1.11 Sens solutions
    • 11.2.2 HEALTHCARE
      • 11.2.2.1 Alere (ABBOTT)
    • TABLE 143 ABBOTT: BUSINESS OVERVIEW
    • FIGURE 44 ABBOTT: COMPANY SNAPSHOT (2021)
      • 11.2.2.2 Roche Diagnostics
    • TABLE 144 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW
    • FIGURE 45 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2021)
      • 11.2.2.3 Hologic
    • TABLE 145 HOLOGIC: BUSINESS OVERVIEW
    • FIGURE 46 HOLOGIC: COMPANY SNAPSHOT (2021)
      • 11.2.2.4 Quidel Corporation
    • TABLE 146 QUIDEL CORPORATION: BUSINESS OVERVIEW
    • FIGURE 47 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)
      • 11.2.2.5 Pro-Lab Diagnostics
  • *Details on Business Overview, Products Offered, Recent Developments, MnM View, SWOT analysis might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS